Opinion|Videos|January 5, 2024
Adverse Events Seen With JAK Inhibitors for Myelofibrosis
Author(s)Christine Cooper, RN, BSN, Aaron Gerds, MD, MS
The JAK inhibitors approved for myelofibrosis have common side effects of cytopenias and gastrointestinal issues, with additional risks of weight gain and cardiac effects and diarrhea; momelotinib and pacritinib show improved tolerability compared to earlier JAK inhibitors.
Advertisement
Episodes in this series
Advertisement
Advertisement
Advertisement
Trending on CURE
1
FDA Updates Safety Warnings for Common Chemotherapy Drugs
2
FDA Removes Use Limitation for Yescarta in Primary CNS Lymphoma
3
Real-World Data with Amtagvi Show High Response Rates in Advanced Melanoma
4
Chemo Brain is Real: My Experience with a Clinical Study and What It Can Teach Us
5